TrialJournal of Crohn's & colitis2025

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.

Geert D'Haens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.